| Nov 15 |
Gain Therapeutics GAAP EPS of -$0.17
|
| Nov 14 |
Gain Therapeutics Reports Financial Results for Third Quarter 2024 and Provides Corporate Update
|
| Oct 23 |
Gain Therapeutics Presents Data at 36ᵗʰ EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics Demonstrating Identification of Allosteric Inhibitors Targeting DDR2
|
| Oct 15 |
Gain Therapeutics Announces Poster Presentation at 36th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
|
| Oct 9 |
Gain Therapeutics to Present at Michael J. Fox Foundation’s 16th Annual Parkinson’s Disease Therapeutics Conference
|
| Oct 7 |
Gain Therapeutics Presents Preclinical GT-02287 Data at Neuroscience 2024
|
| Oct 3 |
Gain Therapeutics to Participate at Upcoming Investor Conferences
|
| Sep 30 |
Gain Therapeutics Presents Phase 1 GT-02287 Data at International Congress of Parkinson’s Disease and Movement Disorders Demonstrating Increase in GCase Activity in Healthy Volunteers
|
| Sep 26 |
Gain Therapeutics To Host Virtual Webinar on Results From Phase 1 Study and Design of Upcoming Phase 1b Trial of GT-02287, a Novel GCase-Targeting Small Molecule Therapy for Parkinson’s Disease
|
| Sep 19 |
Gain Therapeutics to Present Preclinical GT-02287 Data in Parkinson’s Disease Models Including Two Late-Breakers at Neuroscience 2024
|
